Skip to main content
    P

    Prelude Therapeutics Inc (PRLD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.41
    -0.04 (-1.16%)

    Market Cap: $275.32M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Prelude Therapeutics Inc (PRLD) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Prelude Therapeutics are Prothena Corporation (PRTA), Contineum Therapeutics, Inc. Class A Common Stock (CTNM) and Precision BioSciences (DTIL). By market cap, Prelude Therapeutics ranks 7th of the 13 companies on this page; Prothena Corporation (PRTA) is the largest at $419.01M.

    Peer Comparison

    PRLD's revenue growth of 41.0% is above the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Prelude Therapeutics (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)$387.16MN/AN/A0.0%N/A0.0%0.00%
    Precision BioSciences Inc (DTIL)$288.76MN/A4.4x-85.6%-38.3%37272.0%0.00%
    Protara Therapeutics Inc (TARA)$155.77MN/AN/A0.0%N/A0.0%0.00%
    Fulcrum Therapeutics Inc (FULC)$287.96MN/AN/A0.0%N/A-100.0%0.00%
    ProQR Therapeutics BV (PRQR)$199.28MN/A6.1x-228.2%N/A120.4%0.00%
    Bicycle Therapeutics Ltd (BCYC)$236.22MN/A2.7x-169.8%N/A190.2%0.00%
    Lineage Cell Therapeutics Inc (LCTX)$231.35MN/A18.7x16.2%-6.7%-61.0%0.00%
    Protalix Biotherapeutics Inc (PLX)$257.17M12.1x2.9x24.3%N/A22.8%0.00%
    Larimar Therapeutics Inc (LRMR)$313.73MN/AN/A0.0%N/A0.0%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    Century Therapeutics Inc (IPSC)$299.63MN/AN/A0.0%N/A-100.0%0.00%
    Peer median$272.57M12.1x5.2x0.0%-6.7%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Prelude Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
    Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies...
    CTNM competitors
    Precision BioSciences Inc (DTIL)
    Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States.
    DTIL competitors
    Protara Therapeutics Inc (TARA)
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment...
    TARA competitors
    Fulcrum Therapeutics Inc (FULC)
    Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined...
    FULC competitors
    ProQR Therapeutics BV (PRQR)
    ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders.
    PRQR competitors
    Bicycle Therapeutics Ltd (BCYC)
    Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments.
    BCYC competitors
    Lineage Cell Therapeutics Inc (LCTX)
    Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment...
    LCTX competitors
    Protalix Biotherapeutics Inc (PLX)
    Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its...
    PLX competitors
    Larimar Therapeutics Inc (LRMR)
    Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases.
    LRMR competitors
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    Century Therapeutics Inc (IPSC)
    Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy...
    IPSC competitors

    Frequently Asked Questions About PRLD

    Who are Prelude Therapeutics' main competitors?

    The companies most similar to Prelude Therapeutics include Prothena Corporation (PRTA), Contineum Therapeutics, Inc. Class A Common Stock (CTNM), Precision BioSciences (DTIL), Protara Therapeutics (TARA) and Fulcrum Therapeutics (FULC), listed from the closest match.

    Who is Prelude Therapeutics' biggest competitor?

    Prothena Corporation (PRTA) is both the largest of the similar companies at $419.01M and the closest match by business profile, size, sector and industry.

    How does PRLD stock compare with its competitors?

    PRLD's P/S is 16.3x against a peer median of 5.2x; its net margin is -269.7% against a peer median of 0.0%.

    Which of Prelude Therapeutics' competitors pays a higher dividend?

    Prelude Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Prelude Therapeutics bigger than its competitors?

    No. Prelude Therapeutics is 7th by market cap among the 13 companies on this page; the largest is Prothena Corporation (PRTA) at $419.01M.